Cytokinetics Starts ALS Drug Phase II Second Cohort Study

Cytokinetics has started its Phase II trial’s second cohort study of CK-2017357 to treat ALS. CK-2017357 is a skeletal muscle troponin activator, which increases a given muscle cell’s sensitivity to calcium delaying onset and reducing the degree of muscle fatigue. The company is planning to enroll 24 patients from US study centers in this cohort.

Click here to read more.

Share this: